Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Amid shifts in attitudes around family planning and contraception—and as the advent telehealth outfits like Hims & Hers and Ro define a new era of consumer-driven healthcare—the lack of a medic | Recognizing the gap in male birth control, Charlottesville, Virginia’s Contraline is stepping up to the plate, developing what it believes could be a first-in-class topical candidate that has now garnered enthusiasm from a host of big-name investors.
Contraline raised $92.5M Series B to advance NES/T Gel, a first-in-class topical male contraceptive, into phase 3 trials starting 2027. The round signals VC appetite for consumer-driven healthcare in underserved categories, positioning potential telehealth distribution.
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise

Male contraception startup closes $92.5M Series B; Novartis bets on actinium in Phase 3

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

Telehealth booms as demand for GLP-1s surges and questions mount about safety, oversight

Contraline closes $92.5M Series B to fund male contraception; Novartis begins Phase 3 actinium therapies; Tavo gets $17M Series A.

With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…

There’s a thing that happens in American healthcare.You've got these massive systems—pharma conglomerates, hospital networks,…

Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…

Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will